Price List - Ontralfy - Skeletal Muscle Relaxants and Combinations - NA.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-26-Q-9202
- Issued by
-
Defense Health Agency
About this file
This is a price list template for the Department of War (DoW) Pharmacy and Therapeutics (P&T) Committee's May 6-7, 2026 meeting regarding skeletal muscle relaxants and combinations (Ontralfy). The document is a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) pricing template for newly approved pharmaceutical agents in this drug class. Quotes are due by March 26, 2026. The template includes multiple appendices for up to 10 newly approved drugs, with each appendix requiring manufacturers to submit pricing information for both Uniform Formulary (UF) and Non-Formulary (NF) scenarios covering Military Treatment Facility and Mail Order formulary channels. Each drug entry requires pricing per NDC package size and pricing per unit, with all available package sizes (30s, 100s, 1000s) within a given dispensing venue charged at the same price per unit of measure.
The ADP sections require manufacturers to provide pricing for Tier 2 and Tier 3 TRICARE retail refund scenarios. For non-FAMP discount pricing, manufacturers must submit the non-FAMP price of drug per FCP package, additional offered refund per FCP package, and current annual Federal Ceiling Price (FCP) per FCP package. For WAC-based discounts, manufacturers must provide the WAC price of the drug and the WAC discount percentage. The document emphasizes that manufacturers must submit the Quote Submission Checklist and fully executed signature pages along with quote information. Agents not receiving quotes or selected may be designated as non-step preferred (after-step). The P&T Committee may recommend preferential status treating non-generic agents as generic (Tier 1) or recommend complete exclusion from the TRICARE pharmacy benefit program. Prior Authorization may apply to agents in this class.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Cardamyst - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Myqorzo - Cardiovascular Agents Miscellaneous - NA.xlsx | XLSX spreadsheet | |
| Price List - Sdamlo - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Pivya -Antibiotics - Beta-lactams.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9202 NAD.pdf | ||
| Price List - Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction.xlsx | XLSX spreadsheet | |
| Price List - Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263SMNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263SMNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s):This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | SKELETAL MUSCLE RELAXANTS AND COMBINATIONS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263SMNAG1T21M | Tier 2 | 1 or more | |
| 263SMNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .